Strs Ohio Purchases Shares of 21,800 Terns Pharmaceuticals, Inc. $TERN

Strs Ohio purchased a new stake in shares of Terns Pharmaceuticals, Inc. (NASDAQ:TERN) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 21,800 shares of the company’s stock, valued at approximately $881,000.

Several other hedge funds have also bought and sold shares of TERN. GAMMA Investing LLC grew its holdings in Terns Pharmaceuticals by 762.4% during the fourth quarter. GAMMA Investing LLC now owns 871 shares of the company’s stock valued at $35,000 after purchasing an additional 770 shares during the period. Engineers Gate Manager LP purchased a new position in shares of Terns Pharmaceuticals in the second quarter valued at about $41,000. Canada Pension Plan Investment Board purchased a new position in shares of Terns Pharmaceuticals in the second quarter valued at about $46,000. Dynamic Technology Lab Private Ltd purchased a new position in shares of Terns Pharmaceuticals in the first quarter valued at about $51,000. Finally, Polymer Capital Management US LLC purchased a new position in shares of Terns Pharmaceuticals in the third quarter valued at about $76,000. Institutional investors own 98.26% of the company’s stock.

Insider Buying and Selling

In other Terns Pharmaceuticals news, insider Emil Kuriakose sold 942 shares of the company’s stock in a transaction that occurred on Wednesday, April 1st. The stock was sold at an average price of $52.75, for a total transaction of $49,690.50. Following the sale, the insider directly owned 105,673 shares in the company, valued at $5,574,250.75. This represents a 0.88% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, CEO Amy L. Burroughs sold 14,583 shares of the company’s stock in a transaction that occurred on Monday, March 16th. The shares were sold at an average price of $46.71, for a total value of $681,171.93. Following the sale, the chief executive officer owned 288,976 shares in the company, valued at approximately $13,498,068.96. This trade represents a 4.80% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders have sold 30,108 shares of company stock worth $1,302,370. Company insiders own 1.50% of the company’s stock.

Terns Pharmaceuticals Stock Performance

NASDAQ:TERN opened at $52.95 on Friday. The company has a market capitalization of $6.12 billion, a P/E ratio of -51.41 and a beta of -0.37. Terns Pharmaceuticals, Inc. has a 12 month low of $2.65 and a 12 month high of $53.19. The business’s 50-day moving average is $49.68 and its 200 day moving average is $37.90.

Terns Pharmaceuticals (NASDAQ:TERN) last posted its earnings results on Monday, March 30th. The company reported ($0.24) EPS for the quarter, topping analysts’ consensus estimates of ($0.30) by $0.06. On average, research analysts forecast that Terns Pharmaceuticals, Inc. will post -1.22 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on TERN shares. Weiss Ratings restated a “sell (e+)” rating on shares of Terns Pharmaceuticals in a research report on Friday, March 27th. Wall Street Zen downgraded Terns Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Saturday, March 21st. Oppenheimer restated a “market perform” rating and issued a $58.00 price objective on shares of Terns Pharmaceuticals in a research report on Monday, April 27th. William Blair downgraded Terns Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, April 7th. Finally, JPMorgan Chase & Co. boosted their price objective on Terns Pharmaceuticals from $44.00 to $44.50 and gave the company an “overweight” rating in a research report on Tuesday, April 14th. One investment analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, ten have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $55.14.

Terns Pharmaceuticals Company Profile

Terns Pharmaceuticals, Inc is a clinical?stage biopharmaceutical company focused on developing oral small?molecule therapies for the treatment of chronic liver diseases and other serious conditions. The company’s research and development efforts center on novel mechanisms of action designed to address the underlying causes of progressive liver disorders, including inflammation, fibrosis and metabolic dysregulation. By advancing targeted compounds that can be administered orally, Terns aims to offer patients more convenient and effective treatment options compared to injectable or biologic therapies.

The company’s pipeline features several candidates in various stages of preclinical and clinical evaluation.